ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression

REFERENCES

• Wang KC, Chang HY. 2011. Molecular mechanisms of long noncoding RNAs. Mol Cell 43:904–914. https://doi.org/10.1016/j.molcel.2011.08.018.
   PubMed Web of Science ®Google Scholar
• Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigó R. 2012. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22:1775–1789. https://doi.org/10.1101/gr.132159.111.
   PubMed Web of Science ®Google Scholar
• Chu C, Zhang QC, da Rocha ST, Flynn RA, Bharadwaj M, Calabrese JM, Magnuson T, Heard E, Chang HY. 2015. Systematic discovery of Xist RNA binding proteins. Cell 161:404–416. https://doi.org/10.1016/j.cell.2015.03.025.
   PubMed Web of Science ®Google Scholar
• Kopp F, Mendell JT. 2018. Functional classification and experimental dissection of long noncoding RNAs. Cell 172:393–407. https://doi.org/10.1016/j.cell.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. 2016. Long noncoding RNAs in cancer pathways. Cancer Cell 29:452–463. https://doi.org/10.1016/j.ccell.2016.03.010.
   PubMed Web of Science ®Google Scholar
• Mitobe Y, Takayama KI, Horie-Inoue K, Inoue S. 2018. Prostate cancer-associated lncRNAs. Cancer Lett 418:159–166. https://doi.org/10.1016/j.canlet.2018.01.012.
   PubMed Web of Science ®Google Scholar
• Sun M, Gadad SS, Kim DS, Kraus WL. 2015. Discovery, annotation, and functional analysis of long noncoding RNAs controlling cell-cycle gene expression and proliferation in breast cancer cells. Mol Cell 59:698–711. https://doi.org/10.1016/j.molcel.2015.06.023.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. 2010. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076. https://doi.org/10.1038/nature08975.
   PubMed Web of Science ®Google Scholar
• Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung M-C, Lin C, Yang L. 2016. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol 18:213–224. https://doi.org/10.1038/ncb3295.
   PubMed Web of Science ®Google Scholar
• Ghoncheh M, Pournamdar Z, Salehiniya H. 2016. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17:43–46. https://doi.org/10.7314/apjcp.2016.17.s3.43.
   PubMedGoogle Scholar
• Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F. 2015. Precision medicine for metastatic breast cancer–limitations and solutions. Nat Rev Clin Oncol 12:693–704. https://doi.org/10.1038/nrclinonc.2015.123.
   PubMed Web of Science ®Google Scholar
• Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL. 2011. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145:622–634. https://doi.org/10.1016/j.cell.2011.03.042.
   PubMed Web of Science ®Google Scholar
• Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. 2015. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol 12:541–552. https://doi.org/10.1038/nrclinonc.2015.99.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. 2018. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell 33:173–186. https://doi.org/10.1016/j.ccell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. 2009. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631–643. https://doi.org/10.1038/nrc2713.
   PubMed Web of Science ®Google Scholar
• Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ, Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK. 2017. Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell 65:1122–1135. https://doi.org/10.1016/j.molcel.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Oyama M, Nagashima T, Suzuki T, Kozuka-Hata H, Yumoto N, Shiraishi Y, Ikeda K, Kuroki Y, Gotoh N, Ishida T, Inoue S, Kitano H, Okada-Hatakeyama M. 2011. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. J Biol Chem 286:818–829. https://doi.org/10.1074/jbc.M110.156877.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H, Inoue S. 2015. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep 5:13170. https://doi.org/10.1038/srep13170.
   PubMed Web of Science ®Google Scholar
• Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, Takeda S, Inoue S. 2015. MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep 5:7641. https://doi.org/10.1038/srep07641.
   PubMed Web of Science ®Google Scholar
• Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S. 2002. Efp targets 14–3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417:871–875. https://doi.org/10.1038/nature00826.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Orimo A, Higashi Y, Muramatsu M, Inoue S. 2000. Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Lett 472:9–13. https://doi.org/10.1016/s0014-5793(00)01421-6.
   PubMed Web of Science ®Google Scholar
• Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. 2013. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439–1445. https://doi.org/10.1038/ng.2822.
   PubMed Web of Science ®Google Scholar
• Bhan A, Mandal SS. 2016. Estradiol-induced transcriptional regulation of long non-coding RNA, HOTAIR. Methods Mol Biol 1366:395–412. https://doi.org/10.1007/978-1-4939-3127-9_31.
   PubMedGoogle Scholar
• Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, Merkurjev D, Zhang J, Ohgi K, Song X, Oh S, Kim HS, Glass CK, Rosenfeld MG. 2013. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498:516–520. https://doi.org/10.1038/nature12210.
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Stuart JM, Benz CC, Laird PW, Caesar-Johnson SJ, Demchok JA, Felau I, Kasapi M, Ferguson ML, Hutter CM, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang JJ, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Cho J, DeFreitas T, Frazer S, Gehlenborg N, Getz G, Heiman DI, Kim J, Lawrence MS, Lin P, Meier SN. 2018. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173:291–304. https://doi.org/10.1016/J.Cell.2018.03.022.
   PubMed Web of Science ®Google Scholar
• Parise P, Finocchiaro G, Masciadri B, Quarto M, Francois S, Mancuso F, Muller H. 2006. Lap2alpha expression is controlled by E2f and deregulated in various human tumors. Cell Cycle 5:1331–1341. https://doi.org/10.4161/cc.5.12.2833.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Tsukui T, Horie-Inoue K, Inoue S. 2011. Conditional expression of constitutively active estrogen receptor α in osteoblasts increases bone mineral density in mice. FEBS Lett 585:1303–1309. https://doi.org/10.1016/J.Febslet.2011.03.038.
   PubMed Web of Science ®Google Scholar
• Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J. 2016. LncRNA Hotair enhances Er signaling and confers tamoxifen resistance in breast cancer. Oncogene 35:2746–2755. https://doi.org/10.1038/Onc.2015.340.
   PubMed Web of Science ®Google Scholar
• Hudson WH, Pickard MR, de Vera IM, Kuiper EG, Mourtada-Maarabouni M, Conn GL, Kojetin DJ, Williams GT, Ortlund EA. 2014. Conserved sequence-specific lincRNA-steroid receptor interactions drive transcriptional repression and direct cell fate. Nat Commun 5:5395. https://doi.org/10.1038/Ncomms6395.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM. 2018. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for Arlnc1 in prostate cancer progression. Nat Genet 50:814–824. https://doi.org/10.1038/S41588-018-0120-1.
   PubMed Web of Science ®Google Scholar
• Notas G, Pelekanou V, Kampa M, Alexakis K, Sfakianakis S, Laliotis A, Askoxilakis J, Tsentelierou E, Tzardi M, Tsapis A, Castanas E. 2015. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors. Mol Oncol 9:1744–1759. https://doi.org/10.1016/J.Molonc.2015.05.008.
   PubMed Web of Science ®Google Scholar
• Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, Zhai Q, Zhang X, Wu H, Li Y, Li T, Wan X. 2018. Overexpression of Ar-regulated lncRNA Tmpo-As1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate 78:1248–1261. https://doi.org/10.1002/Pros.23700.
   PubMed Web of Science ®Google Scholar
• Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley BW. 1999. A steroid receptor coactivator, Sra, functions As an RNA and is present in an Src-1 complex. Cell 97:17–27. https://doi.org/10.1016/S0092-8674(00)80711-4.
   PubMed Web of Science ®Google Scholar
• Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. 1999. Dd3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979.
   PubMed Web of Science ®Google Scholar
• Misawa A, Takayama K, Urano T, Inoue S. 2016. Androgen-induced long noncoding RNA (lncRNA) Socs2-As1 promotes cell growth and inhibits apoptosis in prostate cancer cells. J Biol Chem 291:17861–17880. https://doi.org/10.1074/Jbc.M116.718536.
   PubMed Web of Science ®Google Scholar
• Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K, Urano T, Fujimura T, Takagi K, Takahashi S, Homma Y, Ouchi Y, Aburatani H, Hayashizaki Y, Inoue S. 2013. Androgen-responsive long noncoding RNA Ctbp1-As promotes prostate cancer. EMBO J 32:1665–1680. https://doi.org/10.1038/Emboj.2013.99.
   PubMed Web of Science ®Google Scholar
• Guil S, Esteller M. 2015. RNA-RNA interactions in gene regulation: the coding and noncoding players. Trends Biochem Sci 40:248–256. https://doi.org/10.1016/J.Tibs.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Sharma E, Sterne-Weiler T, O'Hanlon D, Blencowe BJ. 2016. Global mapping of human RNA-RNA interactions. Mol Cell 62:618–626. https://doi.org/10.1016/j.molcel.2016.04.030.
   PubMed Web of Science ®Google Scholar
• Engreitz JM, Sirokman K, McDonel P, Shishkin AA, Surka C, Russell P, Grossman SR, Chow AY, Guttman M, Lander ES. 2014. RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent pre-mRNAs and chromatin sites. Cell 159:188–199. https://doi.org/10.1016/j.cell.2014.08.018.
   PubMed Web of Science ®Google Scholar
• Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St Laurent G, Kenny PJ, Wahlestedt C. 2008. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 14:723–730. https://doi.org/10.1038/nm1784.
   PubMed Web of Science ®Google Scholar
• Gong C, Maquat LE. 2011. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3’ UTRs via Alu elements. Nature 470:284–288. https://doi.org/10.1038/nature09701.
   PubMed Web of Science ®Google Scholar
• Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. 2008. miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68:5004–5008. https://doi.org/10.1158/0008-5472.CAN-08-0180.
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O. 2009. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 28:3926–3936. https://doi.org/10.1038/onc.2009.241.
   PubMed Web of Science ®Google Scholar
• Namekawa T, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, Ichikawa T, Yano A, Kawakami S, Inoue S. 12 June 2019. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. Int J Cancer. https://doi.org/10.1002/ijc.32505.
   Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725–731. https://doi.org/10.1007/s10549-009-0674-9.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. 2017. National comprehensive cancer network guidelines of treatment of cancer by site. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 25 July 2017.
   Google Scholar
• Sobin LH, Gospodarowicsz MK, Wittekind C. 2009. TNM classification of malignant tumors, 7th ed. John Wiley & Sons, New York, NY.
   Google Scholar
• Suzuki Y, Kitahara S, Suematsu T, Oshima M, Sato Y. 2017. Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts. Cancer Sci 108:2342–2351. https://doi.org/10.1111/cas.13411.
   PubMed Web of Science ®Google Scholar
• Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. 2011. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 44:667–678. https://doi.org/10.1016/j.molcel.2011.08.027.
   PubMed Web of Science ®Google Scholar
• Torres M, Becquet D, Guillen S, Boyer B, Moreno M, Blanchard MP, Franc JL, François-Bellan AM. 2018. RNA pull-down procedure to identify RNA targets of a long non-coding RNA. J Vis Exp 134:57379. https://doi.org/10.3791/57379.
   Google Scholar